{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:16:16Z","timestamp":1777392976535,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10072-022-06260-z","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T13:03:07Z","timestamp":1657544587000},"page":"5709-5716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ditans: a new prospective for the therapy of migraine attack?"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-1563","authenticated-orcid":false,"given":"Giovanna","family":"Viticchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Falsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"6260_CR1","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91:e2222\u2013e2232. https:\/\/doi.org\/10.1212\/WNL.0000000000006641","journal-title":"Neurology"},{"key":"6260_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1177\/0333102409354390","volume":"30","author":"F Sheftell","year":"2010","unstructured":"Sheftell F, Almas M, Weeks R et al (2010) Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia 30:838\u2013846. https:\/\/doi.org\/10.1177\/0333102409354390","journal-title":"Cephalalgia"},{"key":"6260_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1212\/wnl.10.2.107","volume":"10","author":"RW Kimball","year":"1960","unstructured":"Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107\u2013111. https:\/\/doi.org\/10.1212\/wnl.10.2.107","journal-title":"Neurology"},{"key":"6260_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1526-4610.2012.02124.x","volume":"52","author":"C Dahl\u00f6f","year":"2012","unstructured":"Dahl\u00f6f C, Maassen Van Den Brink A (2012) Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache 52:707\u2013714. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02124.x","journal-title":"Headache"},{"key":"6260_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch Neurol 59:1084\u20131088. https:\/\/doi.org\/10.1001\/archneur.59.7.1084","journal-title":"Arch Neurol"},{"key":"6260_CR6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1212\/wnl.55.10.1524","volume":"55","author":"A MaassenVanDenBrink","year":"2000","unstructured":"MaassenVanDenBrink A, van den Broek RW, de Vries R et al (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55:1524\u20131530. https:\/\/doi.org\/10.1212\/wnl.55.10.1524","journal-title":"Neurology"},{"key":"6260_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltr\u00e1n","year":"2018","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Villal\u00f3n CM et al (2018) Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88\u201397. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.005","journal-title":"Pharmacol Ther"},{"key":"6260_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.brainres.2010.09.004","volume":"1361","author":"JD Classey","year":"2010","unstructured":"Classey JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans. Brain Res 1361:76\u201385. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.004","journal-title":"Brain Res"},{"key":"6260_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","volume":"15","author":"M Vila-Pueyo","year":"2018","unstructured":"Vila-Pueyo M (2018) Targeted 5-HT 1F therapies for migraine. Neurotherapeutics 15:291\u2013303. https:\/\/doi.org\/10.1007\/s13311-018-0615-6","journal-title":"Neurotherapeutics"},{"key":"6260_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.bjp.0703081","volume":"129","author":"I Bouchelet","year":"2000","unstructured":"Bouchelet I, Case B, Olivier A et al (2000) No contractile effect for 5-HT1D and 5- HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501\u2013508. https:\/\/doi.org\/10.1038\/sj.bjp.0703081","journal-title":"Br J Pharmacol"},{"key":"6260_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/NDT.S25531","volume":"10","author":"PB Rizzoli","year":"2014","unstructured":"Rizzoli PB (2014) Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat 10:547\u2013552. https:\/\/doi.org\/10.2147\/NDT.S25531","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6260_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1526-4610.2006.00483.x","volume":"46","author":"PL Durham","year":"2006","unstructured":"Durham PL (2006) Calcitonin gene-related peptide (CGRP) and migraine. Headache 46:S3-8. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00483.x","journal-title":"Headache"},{"key":"6260_CR13","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1073\/pnas.83.15.5731","volume":"83","author":"J McCulloch","year":"1986","unstructured":"McCulloch J, Uddman R, Kingman TA et al (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83:5731\u20135735. https:\/\/doi.org\/10.1073\/pnas.83.15.5731","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6260_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40263-013-0126-2","volume":"28","author":"J Hoffmann","year":"2014","unstructured":"Hoffmann J, Goadsby PJ (2014) Emerging targets in migraine. CNS Drugs 28:11\u201317. https:\/\/doi.org\/10.1007\/s40263-013-0126-2","journal-title":"CNS Drugs"},{"key":"6260_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568007043482570","volume":"3","author":"L Lanfumey","year":"2004","unstructured":"Lanfumey L, Hamon M (2004) 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 3:1\u201310. https:\/\/doi.org\/10.2174\/1568007043482570","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"6260_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14656566.2019.1694004","volume":"21","author":"M Curto","year":"2020","unstructured":"Curto M, Cipolla F, Cisale GY et al (2020) Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother 21:147\u2013153. https:\/\/doi.org\/10.1080\/14656566.2019.1694004","journal-title":"Expert Opin Pharmacother"},{"key":"6260_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0014-2999(99)00114-4","volume":"372","author":"T Nilsson","year":"1999","unstructured":"Nilsson T, Longmore J, Shaw D et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372:49\u201356. https:\/\/doi.org\/10.1016\/s0014-2999(99)00114-4","journal-title":"Eur J Pharmacol"},{"key":"6260_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159\u20131169. https:\/\/doi.org\/10.1177\/0333102410370873","journal-title":"Cephalalgia"},{"key":"6260_CR19","unstructured":"FDA Approved Drugs: Reyvow (2019)."},{"key":"6260_CR20","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211280s0001b1.pdf"},{"key":"6260_CR21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN (2019) Lasmiditan: first approval. Drugs 79:1989\u20131996. https:\/\/doi.org\/10.1007\/s40265-019-01225-7","journal-title":"Drugs"},{"key":"6260_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/jcm10071429","volume":"10","author":"M Capi","year":"2021","unstructured":"Capi M, De Angelis V, De Bernardini D et al (2021) CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine. J Clin Med 10:1429. https:\/\/doi.org\/10.3390\/jcm10071429","journal-title":"J Clin Med"},{"key":"6260_CR23","unstructured":"ClinicalTrials.gov (2019) Lasmiditan compared to placebo in the acute treatment of migraine: (SAMURAI). NCT02439320. (Ed.^(Eds) (2019)"},{"key":"6260_CR24","unstructured":"ClinicalTrials.gov (2019) Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). NCT02605174. (Ed.^(Eds) (2019)"},{"key":"6260_CR25","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"P Goadsby","year":"2019","unstructured":"Goadsby P, Wietecha L, Dennehy E et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142:1894\u20131904. https:\/\/doi.org\/10.1093\/brain\/awz134","journal-title":"Brain"},{"key":"6260_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12883-019-1420-5","volume":"19","author":"LS Loo","year":"2019","unstructured":"Loo LS, Plato BM, Turner IM et al (2019) Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol 19:191. https:\/\/doi.org\/10.1186\/s12883-019-1420-5","journal-title":"BMC Neurol"},{"key":"6260_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH et al (2019) Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39:1343\u20131357. https:\/\/doi.org\/10.1177\/0333102419864132","journal-title":"Cephalalgia"},{"key":"6260_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T et al (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia 41:294\u2013304. https:\/\/doi.org\/10.1177\/0333102421989232","journal-title":"Cephalalgia"},{"key":"6260_CR29","doi-asserted-by":"publisher","first-page":"6663591","DOI":"10.1155\/2021\/6663591","volume":"7","author":"P Gu","year":"2021","unstructured":"Gu P, Chen C, Wu Q et al (2021) The effect and safety of 5-HT 1F receptor agonist lasmiditan on migraine: a systematic review and meta-analysis. Biomed Res Int 7:6663591. https:\/\/doi.org\/10.1155\/2021\/6663591","journal-title":"Biomed Res Int"},{"key":"6260_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia 30:1170\u20131178. https:\/\/doi.org\/10.1177\/0333102410375512","journal-title":"Cephalalgia"},{"key":"6260_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","volume":"22","author":"K Johnston","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A et al (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 22:155\u2013166. https:\/\/doi.org\/10.1080\/14737167.2021.1945444","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"6260_CR32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(01)06711-3","journal-title":"Lancet"},{"key":"6260_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M, Diener HC, G\u00e9raud G et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11:405\u2013413. https:\/\/doi.org\/10.1016\/S1474-4422(12)70047-9","journal-title":"Lancet Neurol"},{"key":"6260_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","volume":"21","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Lombard L, Ruff DD et al (2020) Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain 21:20. https:\/\/doi.org\/10.1186\/s10194-020-01088-4","journal-title":"J Headache Pain"},{"key":"6260_CR35","doi-asserted-by":"publisher","unstructured":"Agboola F, Atlas SJ, Touchette DR, et al (2020) The effectiveness and value of novel acute treatments for migraine. J Manag Care Spec Pharm. 26(11):1456\u20131462.https:\/\/doi.org\/10.18553\/jmcp.2020.26.11.1456","DOI":"10.18553\/jmcp.2020.26.11.1456"},{"key":"6260_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-020-00966-z","volume":"60","author":"M Tsai","year":"2021","unstructured":"Tsai M, Nery ESM, Kerr L et al (2021) Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine. Clin Pharmacokinet 60:819\u2013828. https:\/\/doi.org\/10.1007\/s40262-020-00966-z","journal-title":"Clin Pharmacokinet"},{"key":"6260_CR37","unstructured":"ClinicalTrials.gov (2020) A study of\u00a0lasmiditan\u00a0(LY573144) in children aged 6 to 17 with migraine. NCT03988088. (Ed.^(Eds) (2020)"},{"key":"6260_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","volume":"22","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli C, Bragg S, Krege JH et al (2021) Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain 22:132. https:\/\/doi.org\/10.1186\/s10194-021-01343-2","journal-title":"J Headache Pain"},{"key":"6260_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00210-005-1036-8","volume":"371","author":"VL Lucaites","year":"2005","unstructured":"Lucaites VL, Krushinski JH, Schaus JM et al (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 371:178\u2013184. https:\/\/doi.org\/10.1007\/s00210-005-1036-8","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"6260_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4:e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"},{"key":"6260_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","volume":"21","author":"M Hou","year":"2020","unstructured":"Hou M, Xing H, Li C et al (2020) Short-term efficacy and safety of lasmiditan, a novel 5-HT 1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain 21:66. https:\/\/doi.org\/10.1186\/s10194-020-01138-x","journal-title":"J Headache Pain"},{"key":"6260_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732","volume":"35","author":"EM Pearlman","year":"2020","unstructured":"Pearlman EM, Wilbraham D, Dennehy EB et al (2020) Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35:e2732. https:\/\/doi.org\/10.1002\/hup.2732","journal-title":"Hum Psychopharmacol"},{"key":"6260_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1756285614562419","volume":"8","author":"U Reuter","year":"2015","unstructured":"Reuter U, Israel H, Neeb L (2015) The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord 8:46\u201354. https:\/\/doi.org\/10.1177\/1756285614562419","journal-title":"Ther Adv Neurol Disord"},{"key":"6260_CR44","unstructured":"ClinicalTrials.gov (2020) A study of\u00a0lasmiditan\u00a0(LY573144) treatment in children aged 6 to 17 with migraine (PIONEER-PEDS1). NCT04396236. (Ed.^(Eds) (2020)"},{"key":"6260_CR45","unstructured":"ClinicalTrials.gov (2020) A 12-month study of\u00a0lasmiditan\u00a0(LY573144) treatment in children aged 6 to 17 with migraine (PIONEER-PEDS2). NCT04396574. (Ed.^(Eds) (2020)"},{"key":"6260_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1517\/13543784.2014.861817","volume":"23","author":"PC Tfelt-Hansen","year":"2014","unstructured":"Tfelt-Hansen PC, Pihl T, Hougaard A et al (2014) Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 23:375\u2013385. https:\/\/doi.org\/10.1517\/13543784.2014.861817","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06260-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06260-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06260-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:15:56Z","timestamp":1660709756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06260-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6260"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06260-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}